RxDoctor Payments Data

Bethanne Elbert, MD

Internal Medicine · Locust Grove, VANPI 1447298880

Payments from drug & device makers

$13,856in general payments, 2019–2025

Across 933 payments — averaging $14.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Otsuka America Pharmaceutical, Inc.$905
  • Pfizer$768
  • plus $7K from 54 others

What the payments were for

  • Food & beverage$13,70999%
  • Education$1471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)162$1,474
AstraZeneca67$1,431
Novo Nordisk73$1,217
Lilly USA, LLC59$1,009
Otsuka America Pharmaceutical, Inc.59$905
Pfizer90$768
Amgen(2 entities)37$671
Novartis37$634
Lundbeck LLC30$531
Takeda Pharmaceuticals U.S.A., Inc.38$485
GSK36$443
Astellas Pharma US Inc20$375
Bayer20$339
Abbott14$309
Esperion Therapeutics, Inc.19$261
Amarin Pharma, Inc.15$253
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC14$245
Sanofi-aventis U.S. LLC14$211
Biohaven Pharmaceutical Holding Company Ltd.17$203
Kowa Pharmaceuticals America, Inc.10$171
Boehringer Ingelheim8$156
Teva Pharmaceuticals USA, Inc.8$141
Exact Sciences6$132
Axsome Therapeutics, Inc.6$123
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)7$121
Merck8$112
Johnson & Johnson5$82
E.r. Squibb & Sons, L.L.C.5$73
Phathom Pharmaceuticals, Inc.3$69
Idorsia Pharmaceuticals US Inc3$62
Atricure, Inc.2$59
Boston Scientific2$51
Sumitomo Pharma America, Inc.2$48
Medicomp Inc2$46
Biohaven Pharmaceuticals, Inc.2$45
Dexcom, Inc.2$44
Jazz Pharmaceuticals Inc.2$37
Corium, LLC1$34
Medtronic(2 entities)2$32
Tris Pharma Inc2$30
Ardelyx, Inc.2$29
Sanofi Pasteur Inc.2$29
Lifescan, Inc.1$26
Bausch Health US, LLC1$24
Daiichi Sankyo Inc.1$24
Avanir Pharmaceuticals, Inc.1$24
Duchesnay USA Incorporated1$23
Endo Pharmaceuticals Inc.1$20
Eisai Inc.1$20
Irhythm Technologies, Inc.1$20
Sanofi1$20
Philips North America LLC1$18
Scilex Pharmaceuticals Inc.1$17
Paratek Pharmaceuticals, Inc.1$17
Sunovion Pharmaceuticals Inc.1$16
Edwards Lifesciences1$16
Actelion Pharmaceuticals US, Inc.1$15
AMAG Pharmaceuticals, Inc.1$15
Inspire Medical Systems, Inc.1$15
Insightec,inc1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,856 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$507,972
Medicare patients
1,001
Services billed
7,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$94,253
EliquisApixaban58$80,026
MounjaroTirzepatide55$67,378
TrulicityDulaglutide45$52,083
RybelsusSemaglutide39$46,754
JanuviaSitagliptin Phosphate38$46,067
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$42,534
FarxigaDapagliflozin Propanediol43$37,734
RexultiBrexpiprazole14$27,511
JardianceEmpagliflozin27$22,637
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$22,346
Repatha SureclickEvolocumab17$18,772
BelsomraSuvorexant24$16,169
Janumet XrSitagliptin Phos/Metformin Hcl14$7,705
Rosuvastatin Calcium325$5,430

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,217$141,007119 claims
Lilly USA, LLCMounjaro, Trulicity$1,009$119,462100 claims
PfizerEliquis$768$80,02658 claims
MerckJanuvia, Belsomra, Janumet Xr$112$69,94176 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,431$60,08059 claims
GSKTrelegy Ellipta$443$42,53433 claims
Otsuka America Pharmaceutical, Inc.Rexulti$905$27,51114 claims
Boehringer IngelheimJardiance$156$22,63727 claims
AbbVieSynthroid$1,474$3,34354 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Locust Grove

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →